Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 0 points (0.0%) at 18,120 as of Tuesday, June 23, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,375 declining with 175 unchanged. The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Novavax ( NVAX), up 7.9%, Vertex Pharmaceuticals ( VRTX), up 1.6%, Perrigo ( PRGO), up 1.5%, Shire ( SHPG), up 0.8% and Sanofi ( SNY), up 0.8%. On the negative front, top decliners within the industry include Biomarin Pharmaceutical ( BMRN), down 1.9%, Alnylam Pharmaceuticals ( ALNY), down 1.9%, Incyte ( INCY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $3.81 (1.2%) to $311.06 on average volume. Thus far, 1.1 million shares of Allergan exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $308.07-$312.37 after having opened the day at $308.20 as compared to the previous trading day's close of $307.25. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $118.7 billion and is part of the health care sector. Shares are up 19.4% year-to-date as of the close of trading on Monday. Currently there are 15 analysts who rate Allergan a buy, no analysts rate it a sell, and 1 rates it a hold. TheStreet Ratings rates Allergan as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Allergan Ratings Report now. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.